F-star Therapeutics to Participate in Upcoming Conferences

Rhea-AI Summary

F-star Therapeutics, a clinical-stage biopharmaceutical company, announces participation in three upcoming virtual events: the H.C. Wainwright BioConnect Conference, LifeSci Advisors 10th Annual Corporate Access Event, and B Riley Oncology Investor Conference. CEO Eliot Forster will lead discussions and presentations detailing the company’s progress and pipeline. Key dates include January 6-14 for 1x1 meetings and January 20 for the investor conference. F-star aims to innovate cancer therapies through its proprietary bispecific antibodies and enhance patient outcomes.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces that members of the management team will be participating in the H.C. Wainwright BioConnect Conference, the LifeSci Advisors 10th Annual Corporate Access Event and the B Riley Oncology Event. All events will take place virtually.

Details for the events are as follows:

H.C. Wainwright BioConnect Conference

Fireside chat with CEO, Eliot Forster
Dates: January 11-14, 2021

LifeSci Advisors 10th Annual Corporate Access Event

1x1 Meetings with Management
Dates: January 6-8, 11-14, 2021

B Riley Oncology Investor Conference

Presentation by CEO, Eliot Forster
Date: January 20, 2021
Time: 11:30am – 12:00pm

Eliot Forster, CEO of F-star Therapeutics, Inc., said: “Having listed on NASDAQ at the end of 2020, we are looking forward to the opportunity to discuss the Company, our pipeline and our most recent progress at these events. We have had numerous updates across our four clinical programs in recent months and continue our dedication to developing next generation immunotherapies to transform the lives of patients with cancer.”

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com.

For further information, please contact:

For investor inquiries Lindsey Trickett VP Investor Relations & Communications +1 240 543 7970 lindsey.trickett@f-star.com

For media inquiries Next Step Communications Nigel Smith +1 781 326 1741 F-star@nextstepcomms.com

FAQ

What events is F-star Therapeutics participating in January 2021?

F-star Therapeutics is participating in the H.C. Wainwright BioConnect Conference, LifeSci Advisors 10th Annual Corporate Access Event, and B Riley Oncology Investor Conference.

When is the H.C. Wainwright BioConnect Conference?

The H.C. Wainwright BioConnect Conference takes place from January 11-14, 2021.

What are the details for the LifeSci Advisors Corporate Access Event?

The LifeSci Advisors 10th Annual Corporate Access Event includes 1x1 meetings with management from January 6-8 and January 11-14, 2021.

When will F-star present at the B Riley Oncology Investor Conference?

F-star will present at the B Riley Oncology Investor Conference on January 20, 2021, from 11:30am to 12:00pm.

What is F-star Therapeutics' focus in cancer therapy?

F-star Therapeutics focuses on developing next-generation immunotherapies, specifically tetravalent bispecific antibodies, to improve patient outcomes in cancer treatment.